CTO Buys Shares Amid 40% Drop: Signals Confidence and Growth Plans
CTO’s $0.81 share purchase amid a 40% monthly drop signals confidence in Rani’s oral biologics pipeline and tech‑driven growth strategy.
- Rani Therapeutics Holdings Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read